Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017-2018.
Antimalarial
Artemether-lumefantrine
Burkina faso
Dihydroartemisinin-piperaquine
Efficacy
Plasmodium falciparum
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
19 Jan 2021
19 Jan 2021
Historique:
received:
19
10
2020
accepted:
07
01
2021
entrez:
20
1
2021
pubmed:
21
1
2021
medline:
3
8
2021
Statut:
epublish
Résumé
The World Health Organization recommends regularly assessing the efficacy of artemisinin-based combination therapy (ACT), which is a critical tool in the fight against malaria. This study evaluated the efficacy of two artemisinin-based combinations recommended to treat uncomplicated Plasmodium falciparum malaria in Burkina Faso in three sites: Niangoloko, Nanoro, and Gourcy. This was a two-arm randomized control trial of the efficacy of artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP). Children aged 6-59 months old were monitored for 42 days. The primary outcomes of the study were uncorrected and PCR-corrected efficacies to day 28 for AL and 42 for DP. Molecular markers of resistance to artemisinin derivatives and partner drugs were also analysed. Of 720 children enrolled, 672 reached study endpoints at day 28, 333 in the AL arm and 339 in the DP arm. PCR-corrected 28-day per protocol efficacy in the AL arm was 74% (64-83%) in Nanoro, 76% (66-83%) in Gourcy, and 92% (84-96%) in Niangoloko. The PCR-corrected 42-day per protocol efficacy in the DP arm was 84% (75-89%) in Gourcy, 89% (81-94%) in Nanoro, and 97% (92-99%) in Niangoloko. No Pfk13 mutation previously associated with artemisinin-resistance was observed. No statistically significant association was found between treatment outcome and presence of the 86Y mutation in the Pfmdr1 gene. There was also no association observed between treatment outcome and Pfpm2 or Pfmdr1 copy number variation. The results of this study indicate evidence of inadequate efficacy of AL at day 28 and DP at day 42 in the same two sites. A change of first-line ACT may be warranted in Burkina Faso. Trial Registry Pan African Clinical Trial Registry Identifier: PACTR201708002499311. Date of registration: 8/3/2017 https://pactr.samrc.ac.za/Search.aspx.
Sections du résumé
BACKGROUND
BACKGROUND
The World Health Organization recommends regularly assessing the efficacy of artemisinin-based combination therapy (ACT), which is a critical tool in the fight against malaria. This study evaluated the efficacy of two artemisinin-based combinations recommended to treat uncomplicated Plasmodium falciparum malaria in Burkina Faso in three sites: Niangoloko, Nanoro, and Gourcy.
METHODS
METHODS
This was a two-arm randomized control trial of the efficacy of artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP). Children aged 6-59 months old were monitored for 42 days. The primary outcomes of the study were uncorrected and PCR-corrected efficacies to day 28 for AL and 42 for DP. Molecular markers of resistance to artemisinin derivatives and partner drugs were also analysed.
RESULTS
RESULTS
Of 720 children enrolled, 672 reached study endpoints at day 28, 333 in the AL arm and 339 in the DP arm. PCR-corrected 28-day per protocol efficacy in the AL arm was 74% (64-83%) in Nanoro, 76% (66-83%) in Gourcy, and 92% (84-96%) in Niangoloko. The PCR-corrected 42-day per protocol efficacy in the DP arm was 84% (75-89%) in Gourcy, 89% (81-94%) in Nanoro, and 97% (92-99%) in Niangoloko. No Pfk13 mutation previously associated with artemisinin-resistance was observed. No statistically significant association was found between treatment outcome and presence of the 86Y mutation in the Pfmdr1 gene. There was also no association observed between treatment outcome and Pfpm2 or Pfmdr1 copy number variation.
CONCLUSION
CONCLUSIONS
The results of this study indicate evidence of inadequate efficacy of AL at day 28 and DP at day 42 in the same two sites. A change of first-line ACT may be warranted in Burkina Faso. Trial Registry Pan African Clinical Trial Registry Identifier: PACTR201708002499311. Date of registration: 8/3/2017 https://pactr.samrc.ac.za/Search.aspx.
Identifiants
pubmed: 33468147
doi: 10.1186/s12936-021-03585-6
pii: 10.1186/s12936-021-03585-6
pmc: PMC7816451
doi:
Substances chimiques
Antimalarials
0
Artemether, Lumefantrine Drug Combination
0
Artemisinins
0
Quinolines
0
artenimol
6A9O50735X
piperaquine
A0HV2Q956Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
48Références
Trop Med Int Health. 2014 Apr;19(4):469-75
pubmed: 24494602
Malar J. 2015 Aug 20;14:325
pubmed: 26289949
Clin Pharmacokinet. 1999 Aug;37(2):105-25
pubmed: 10496300
Parasitol Today. 1998 Nov;14(11):462-7
pubmed: 17040849
Lancet Infect Dis. 2016 Feb;16(2):189-98
pubmed: 26601738
Bull Soc Pathol Exot. 2009 Feb;102(1):31-5
pubmed: 19343918
Am J Trop Med Hyg. 2013 Apr;88(4):757-64
pubmed: 23382166
Am J Trop Med Hyg. 2014 Oct;91(4):833-843
pubmed: 25048375
Philos Trans R Soc Lond B Biol Sci. 1999 Apr 29;354(1384):739-49
pubmed: 10365399
J Infect Dis. 2016 Jan 1;213(1):90-9
pubmed: 26142435
BMC Med. 2016 Oct 24;14(1):167
pubmed: 27776521
Ann Glob Health. 2014 Nov-Dec;80(6):458-65
pubmed: 25960095
BMC Med Res Methodol. 2019 Nov 27;19(1):215
pubmed: 31775647
Bull Soc Pathol Exot. 2012 Aug;105(3):202-7
pubmed: 22322791
Lancet Infect Dis. 2017 Feb;17(2):174-183
pubmed: 27818097
Cold Spring Harb Perspect Med. 2017 Jul 5;7(7):
pubmed: 28289248
Nat Med. 2020 Oct;26(10):1602-1608
pubmed: 32747827
Malar J. 2017 Feb 6;16(1):63
pubmed: 28166794
Lancet Infect Dis. 2017 Feb;17(2):164-173
pubmed: 27818095
Malar J. 2018 Oct 5;17(1):347
pubmed: 30290808
Malar J. 2013 Nov 09;12:405
pubmed: 24206649
Lancet Infect Dis. 2017 Dec;17(12):1266-1275
pubmed: 28916443
J Glob Antimicrob Resist. 2015 Jun;3(2):58-63
pubmed: 27873670
N Engl J Med. 2016 Jun 23;374(25):2453-64
pubmed: 27332904
Malar J. 2010 Dec 20;9:366
pubmed: 21171998